Target the Gene
Silence the Disease


Phase 1
Phase 2
Phase 3
  • ARC-520 (Hepatitis B)
    Hepatitis B
  • ARC-521 (Hepatitis B)
    Hepatitis B
  • ARC-AAT (Alpha-1 Antitrypsin Deficiency)
    Alpha-1 Antitrypsin Deficiency
  • ARC-F12 (Thrombosis and Angioedema)
    Thrombosis and Angioedema
  • ARC-LPA (Cardiovascular Disease)
    Cardiovascular Disease
  • ARC-HIF2 (Clear Cell, Renal Cell Carcinoma)
    Clear Cell, Renal Cell Carcinoma


Arrowhead has established a robust and versatile drug discovery and development platform based on proprietary technologies, broad licenses to fundamental intellectual property and extensive scientific expertise after more than a decade working on RNAi-based therapies.

Learn More

About Arrowhead

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes.



Learn More